- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01218529
Lapatinib and WBRT for Patients With Brain Metastases From Lung or Breast Tumors
Lapatinib and Whole Brain Radiotherapy for Patients With Brain Metastases From Lung and Breast Tumors. A Phase II Study of the Hellenic Cooperative Oncology Group (HeCOG).
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Athens, Greece, 11527
- Sotiria General Hospital, 3rd Dept of Medicine, Oncology Unit
-
Athens, Greece, 11528
- General Peripheral Hospital of Athens "Alexandra"
-
Athens, Greece, 15123
- Hygeia Hospital, 2nd Dept of Medical Oncology
-
Athens, Greece, 18547
- Metropolitan Hospital, 1st Dept of Medical Oncology
-
Athens, Greece, 18547
- Metropolitan Hospital, 2nd Dept of Medical Oncology
-
Athens, Greece, 14564
- Agii Anargiri Cancer Hospital, 3rd Dept of Medical Oncology
-
Athens, Greece, 11527
- General Hospital of Athens 'Hippokratio', 2nd Dept of Internal Medicine
-
Athens, Greece, 15123
- Hygeia Hospital, 1st Dept of Medical Oncology
-
Chania, Greece, 73100
- Chania General Hospital, Oncology Section
-
Ioannina, Greece, 45110
- Ioannina University Hospital, Dept of Medical Oncology
-
Larissa, Greece, 44110
- University Hospital of Larissa, Dept of Internal Medicine, Oncology Section
-
Patras, Greece, 26500
- Rio University Hospital, Dept of Medical Oncology
-
Thessaloniki, Greece, 56429
- Papageorgiou General Hospital, Dept of Medical Oncology
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Signed written informed consent;
- Age >=18 years old;
- Eastern Cooperative Oncology Group (ECOG) Performance Status 0-2;
- Life expectancy of at least 12 weeks;
- Subjects must have histologically or cytologically confirmed invasive lung or breast cancer, with Stage IV disease;
- Epidermal growth factor receptor (ErbB1/EGFR) overexpressing primary tumour, defined as 2+/3+ staining by immunohistochemistry (IHC) is mandatory to assess the patient population, but it is not a requirement for study entry.
- At least one measurable lesion in the brain, defined as any lesion >= 10mm in longest dimension on T1-weighted, gadolinium-enhanced MRI;
- Cardiac ejection fraction within institutional range of normal as measured by echocardiogram. Multigated acquisition scan (MUGA) scans will be accepted in cases where an echocardiogram cannot be performed or is inconclusive;
- At least 3 weeks since last chemotherapy, immunotherapy, biologic therapy, or hormonal therapy for cancer, and sufficiently recovered or stabilized from side effects associated with prior therapy. Concurrent treatment with bisphosphonates is permitted;
- At least 3 weeks since major surgical procedures;
- Able to swallow and retain oral medications;
- Female subjects with child bearing potential or male subjects able to father a child must be completely abstinent from intercourse or use acceptable methods for birth control during the course of the study;
- Subjects must complete all screening assessments as outlined in the protocol;
- Subjects must have normal organ and marrow function as defined below:
SYSTEM LABORATORY VALUES Hematologic Absolute neutrophil count (ANC) 1.0 x 109/L Hemoglobin >= 9 g/dL (after transfusion if needed) Platelets >= 50 x 109/L Hepatic Albumin >= 2.5 g/dL Serum bilirubin <= 1.5x ULN unless due to Gilbert's syndrome Aspartate aminotransferase (AST) and Alaninine Aminotransferase (ALT) <= 5x upper limit of normal (ULN) if documented liver metastases <= 3x ULN without liver metastases Renal Serum Creatinine <= 2.0 mg/dL or Calculated Creatinine Clearance* >= 25 mL/min*Calculated by the Cockcroft and Gault Method
Exclusion Criteria:
- Subjects are suitable for brain surgery or stereotactic radiosurgery (SRS);
- Subjects who have had prior cranial radiotherapy. Prior radiotherapy for lesions outside CNS is allowed.
- Subjects who have had chemotherapy or radiotherapy within 2 weeks prior to entering the study or who have unresolved or unstable, serious toxicity from prior administration of another investigational drug and/or of prior cancer treatment;
- Concurrent treatment with an investigational agent or participation in another treatment clinical trial;
- Subjects receiving concurrent chemotherapy, radiation therapy, immunotherapy, biologic therapy (including an ErbB1 and/or ErbB2 inhibitor), or hormonal therapy for treatment of their non-CNS cancer. Concurrent treatment with bisphosphonates is allowed;
- Subjects with leptomeningeal carcinomatosis as the only site of CNS involvement;
- History of allergic reactions attributed to compounds of similar chemical composition (quinazolines) to lapatinib;
- Concurrent treatment with medications that are either inducers or inhibitors of CYP3A4 is prohibited. (For important exceptions, refer to Section Prohibited Medications);
- Malabsorption Syndrome, disease significantly affecting gastrointestinal function, or resection of the stomach or small bowel. Subjects with active, uncontrolled ulcerative colitis are also excluded;
- Any underlying liver or biliary disease (except for patients with Gilbert syndrome, asymptomatic cholelithiasis, liver metastases or stable chronic liver disease according to the physician)
- Other known contraindication to MRI, such as a cardiac pacemaker, implanted cardiac defibrillator, brain aneurysm clips, cochlear implant, ocular foreign body, or shrapnel;
- Concurrent disease or condition that would make the subject inappropriate for study participation or any serious medical or psychiatric disorder that would interfere with the subject's safety;
- Dementia, altered mental status, or any psychiatric condition that would prohibit the understanding or rendering of informed consent;
- Pre-existing severe cerebral vascular disease, such as stroke involving a major vessel, CNS vasculitis, or malignant hypertension;
Active cardiac disease, defined as one or more of the following:
- History of uncontrolled or symptomatic angina
- History of arrhythmias requiring medications, or clinically significant, with the exception of asymptomatic atrial fibrillation requiring anticoagulation
- Myocardial infarction < 6 months from study entry
- Uncontrolled or symptomatic congestive heart failure
- Ejection fraction below the institutional normal limit
- Any other cardiac condition, which in the opinion of the treating physician, would make this protocol unreasonably hazardous for the patient
- Uncontrolled infection;
- History of other malignancy, except for curatively treated basal cell carcinoma or squamous cell carcinoma of the skin, or carcinoma in situ of the cervix. Subjects with other malignancies who have been disease-free for at least 5 years are eligible;
- Pregnant or lactating females.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Whole Brain Radiation Therapy (WBRT) + lapatinib
Whole Brain Radiation Therapy (30Gy in 10 fractions) and lapatinib 1250mg once daily for 2 weeks followed by lapatinib treatment 1500mg once daily for 4 weeks.
|
Co-administration of lapatinib 1250mg once daily during the WBRT period (2 weeks)and then monotherapy with lapatinib 1500mg once daily for 4 weeks.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Response rate in brain as assessed by volumetric analysis of brain Mangnetic Resonance Imaging (MRI).
Time Frame: At the 6 weeks timepoint, radiological assessment with brain MRI will take place to evaluate the response of the patients
|
At the 6 weeks timepoint, radiological assessment with brain MRI will take place to evaluate the response of the patients
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Response rate for systemic disease
Time Frame: At 6 weeks
|
Chest, abdomen, and pelvic Computerized Tomography (CT) scans will be performed at the 6 weeks timepoint to evaluate the response for systemic disease
|
At 6 weeks
|
Time To Progression in brain and/or non-Central Nervous System (CNS)
Time Frame: At the 6 weeks timepoint, radiological assessment with brain MRI will take place to evaluate the response of the patients.The patients will be followed-up every 12 weeks for disease progression and survival.
|
At the 6 weeks timepoint, radiological assessment with brain MRI will take place to evaluate the response of the patients.The patients will be followed-up every 12 weeks for disease progression and survival.
|
|
Safety and tolerability of proposed schema. Adverse Events (AEs) of all participants will be recorded and assessed upon signature of the informed consent form, until 30 days after the last administration of study treatment.
Time Frame: 10 weeks (6 weeks therapy + 4 weeks follow-up period for AEs)
|
Adverse Events will be graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v3.0 criteria and will be reported in a frequency table according to the highest severity grade observed per patient.
|
10 weeks (6 weeks therapy + 4 weeks follow-up period for AEs)
|
To explore the 20% volumetric reduction of brain metastatic lesions as a meaningful threshold of CNS response.
Time Frame: At the 6 weeks timepoint, radiological assessment with brain MRI will take place to evaluate the response of the patients.
|
At the 6 weeks timepoint, radiological assessment with brain MRI will take place to evaluate the response of the patients.
|
Collaborators and Investigators
Investigators
- Study Chair: Christos Christodoulou, MD, Metropolitan Hospital, 2nd Dept of Medical Oncology
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Skin Diseases
- Neoplasms by Site
- Breast Diseases
- Neoplastic Processes
- Central Nervous System Neoplasms
- Nervous System Neoplasms
- Neoplasms
- Breast Neoplasms
- Neoplasm Metastasis
- Brain Neoplasms
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antineoplastic Agents
- Protein Kinase Inhibitors
- Lapatinib
Other Study ID Numbers
- HE 42/09
- 2009-013128-22 (EudraCT Number)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Breast Tumors
-
Emory UniversityEisai Inc.TerminatedBreast Cancer | Breast Neoplasms | Breast Tumors | Neoplasms, Breast | Cancer of the Breast | Tumors, BreastUnited States
-
AmgenCompletedCancer | Breast Cancer | Breast Neoplasms | Metastatic Cancer | Breast Tumors | Solid Tumors | Oncology | Tumors | Metastases | Locally Recurrent and Metastatic Breast CancerUnited States, Belgium, France
-
NSABP Foundation IncRoyal Marsden NHS Foundation Trust; Pfizer; Institute of Cancer Research, United...CompletedBreast Cancer | Breast Tumors | Breast CarcinomaUnited Kingdom, United States, Canada
-
Sichuan Provincial People's HospitalRecruiting
-
State University of New York - Upstate Medical...Completed
-
UNICANCERDaiichi Sankyo Europe, GmbH, a Daiichi Sankyo CompanyActive, not recruiting
-
National University Hospital, SingaporeUnknown
-
GE HealthcareTerminatedBreast Cancer | Tumors, BreastFrance, United States
-
GE HealthcareTerminatedBreast Cancer | Tumors, BreastUnited States
-
Emory UniversityNovartis; Eisai Inc.TerminatedBreast Cancer | Breast Neoplasms | Breast TumorsUnited States
Clinical Trials on Lapatinib
-
GlaxoSmithKlineCompletedCancerUnited States
-
Institut Paoli-CalmettesSuspended
-
German Breast GroupTerminatedMetastatic Breast CancerGermany
-
R-PharmGlaxoSmithKlineTerminatedLocally Advanced or Metastatic Breast CancerUnited States, Italy, Australia
-
Georgetown UniversityGlaxoSmithKlineCompletedHead and Neck Cancer | Colorectal Cancer | Lung CancerUnited States
-
University of Alabama at BirminghamGlaxoSmithKlineTerminatedOvarian CancerUnited States
-
Tragara Pharmaceuticals, Inc.Terminated
-
GlaxoSmithKlineCompletedColorectal CancerUnited States, Canada
-
GlaxoSmithKlineTerminatedNeoplasms, BreastItaly, United Kingdom
-
GlaxoSmithKlineCompletedNeoplasms, BreastUnited States, Israel